Key result
Antiplatelet therapy after ACS faces poor initiation and ~85% subsequent discontinuation among initial users.
Why the study?
To investigate the initiation and persistence of antiplatelet agents and associated factors among patients with ACS in Tianjin, China.
Population
21,450 adult patients discharged alive after first ACS-related hospitalization in Tianjin, China
Comparison
Factors associated with initiation and persistence of antiplatelet agents
Design
Retrospective observational database study
Authors
Loading...
Suboptimal antiplatelet initiation and persistence after ACS in Tianjin warrants targeted adherence efforts; leaves open whether addressing PCI, prior use, or sex differences improves outcomes.
Observational (n=21,450)
Real-world initiation and persistence of antiplatelet therapy after ACS in China is remarkably poor, with high discontinuation rates particularly among females and those not receiving PCI.
Liu et al. (2019) conducted an observational in Acute coronary syndromes (ACS) (n=21,450). Antiplatelet agents was evaluated on Initiation of antiplatelet agents within 30 days of discharge. Among ACS patients in Tianjin, China, only 70.3% initiated antiplatelet therapy within 30 days of discharge, and 85.0% of these initial users subsequently discontinued therapy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: